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Predictive value of c-erbB-2, p53, cathepsin-D and
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Summary The value of various prognostic factors in breast cancer patients has been determined in a number of studies. Few reports have
been published on the dependence of treatment outcome on histological and immunohistochemical characteristics in the primary tumour in
patients with metastatic disease. We studied the incidence and prognostic value of histological and molecular abnormalities in the primary
tumour of patients who had developed metastatic breast cancer. Eligible patients received a fluorouracil, epirubicin and cyclophosphamide
(FEC) regimen either once a week or once every 4 weeks. Adequate specimens for various analyses were available from 127 patients.
Median follow-up time of the patients ranged from 15 to 101 months. In this study, the histological grade of the malignancy best predicted
response to chemotherapy (P < 0.0005). Most of the responses were observed in patients with grade 1 tumours; in this group, time to
progression was delayed. C-erb B-2 gene amplification and oncoprotein expression had no predictive value. Neither p53 nor cathepsin-D
predicted treatment outcome after chemotherapy. None of the factors had an effect on overall survival. Among breast cancer patients who
received anthracycline-containing chemotherapy, response to treatment correlated with histological grade. In patients with histological grade
1 breast cancer, the time to progression was longest. However, overall survival was not affected by histological grade nor the other
parameters tested. In addition to histological grade, other prognostic factors that are not included in this study need to be identified to
determine which patients with metastatic breast cancer would benefit from cytotoxic treatment.
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In the assessment of breast cancer patients, tumour size, steroid
hormone receptors, axillary node status, cell kinetics and ploidy
are well-established prognostic factors (Elledge et al, 1992).
Recently, a number of new probes have been developed to detect
molecular abnormalities that are only observed in malignant cells.
However, the grading of malignant histological features by an
experienced pathologist may have a powerful predictive value.
The histological grade is an estimate ofthree components: mitotic
frequency, tubule formation and nuclear pleomorphism (Elston,
1987; Blamey and Galea, 1994).
Perhaps, the most extensively studied new prognostic factor is
the c-erbB-2 oncogene, also known as HER-2/neu. The corre-
sponding oncoprotein is a 185-kDa receptor with tyrosine kinase
activity (Cousseus et al, 1985). Studies on the expression of this
oncogene have demonstrated that amplification can be observed in
15-30% ofpatients with breast tumours, and this has been associ-
ated with shorter survival mainly in node-positive patients (Slamon
et al, 1987; Varley et al, 1987; Van de Vivjer et al, 1988; Slamon et
al, 1989; Tandon et al, 1989; Walker et al, 1989; Borg et al, 1990).
This conclusion has notbeen supported by datapresentedby others
(Barnes et al, 1988; Zhou et al, 1989; Heintz et al, 1990; Parkes et
al, 1990). Another well-studied gene has beenp53, which appears
to inhibit the progression ofcells from theGI to the S-phase during
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the cell cycle (Marx, 1993; Levine et al, 1994). Mutations in that
gene are considered to contribute to the development of human
cancer in approximately half of the cases. The data presented on
cathepsin-D indicate that the high tumour levels of this factor are
related to poor survival (Klijn et al, 1993 a and b).
Patients with metastatic breast cancer are routinely treated with
either endocrine therapy or chemotherapy. Only half of the
patients benefit from these treatments. Therefore, efforts have
been made to identify patients who respond to hormonal manipu-
lations orcytotoxic agents. So far, high tumour levels ofoestrogen
receptor (ER), progesterone receptor (PgR), androgen receptor
(AR) and p53 have shown a good response to hormonal manipula-
tions (Elledge et al, 1992). In contrast, epidermal growth factor
receptor (EGF-R) positivity, c-erbB-2 positivity (Elledge et al,
1992), high proliferation indices, aneuploidy and possibly high
uPA levels indicate a poor response to endocrine therapy (Klijn et
al, 1993 a and b). There are very few data available on factors for
predicting chemotherapy response in breast cancer. In metastatic
breast cancer, a high proliferation rate and c-erbB-2 amplification
have been associated with good response, whereas multidrug
resistance (MDR) gene expression and possibly c-myc amplifica-
tion have been considered as predictors ofpoor response (Klijn et
al, 1993 a and b).
In this study, we assessed the predictive value ofseveral factors
for chemotherapy response and prognosis in patients who were
treated with the FEC regimen for metastatic disease within a
randomized trial (Blomqvist et al, 1993). The patients received
equal doses of FEC chemotherapy either once a week or every 4
weeks. It was demonstrated that both the efficiency and the toxi-
city of FEC were greater when treatment was administered every
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Table 1 Characteristics of patients developing metastatic breast cancer
Characteristics Number of patients %
Patients enrolled in the study 173
Specimens obtained for histology 130 75
Histology consistent with ductal or lobular
breast cancer 121 70
Histology
Ductal 93/121 77
Lobular 28/121 23
Patients assessable for response 103
Treatment
FEC every 28 days 56 54
FEC every 7 days 47 46
Median age (years) 54
Menopausal status
Premenopausal 55 53
Post-menopausal 45 44
Unknown 3 3
ER status
Positive 60 63
Negative 36 38
PR status
Positive 60 63
Negative 36 38
Median disease-free interval (months) 16
Previous treatment (n) 59 57
Previous cytotoxic treatment (n) 15 15
Soft tissue metastases (n) 16 16
Bone metastases only (n) 11 11
Visceral metastases (n) 76 74
4 weeks rather than once a week. The dependence of treatment
outcome on histological grade, c-erbB-2 oncogene amplification,
c-erbB-2 oncoprotein expression, p53 mutation and cathepsin-D
levels in the primary tumour was determined.
MATERIALS AND METHODS
Patients and tumour material
A total of 173 patients with metastatic breast cancer were initially
enrolled in the study (Blomqvist etal, 1993; Table 1). Patients who
had received adjuvant therapy or hormonal treatment for
metastatic disease were accepted in the study. For laboratory
studies, paraffin-embedded blocks from 130 patients were
obtained. After further analysis, nine patients were excluded
because of medullary carcinoma (n = 1), intraductal carcinoma
(n = 4), metastases from other malignancies (n = 2), early death
(n = 1) and metastatic disease unproven (n = 1). The remaining
121 patients were evaluated for survival. Three patients were
excluded from analysis of TTP (time to progression) because of
non-cancer death (pulmonary embolism, pneumonia) or change of
therapy without a documented reason. Response to chemotherapy
according to UICC criteria (Hayward et al, 1977) could be
assessed only in 103 patients. An additional 18 patients had to be
excluded because they received simultaneous radiotherapy (n = 8),
amodified chemotherapy regimen (n = 5), simultaneous endocrine
treatment (n = 2) orhad surgical excision ofthe only lesion (n = 2).
Total monthly doses in the two groups consisted of 5-fluorouracil
500mgm-2, epirubicin 60mgm-2 and cyclophosphamide
500 mg m-2. The variable number ofanalysed samples is indicated
separately in the tables.
Table 2 The relationship between histological grade and chemotherapy
response
Grade Response to treatment
PD NC PR CR Total
7 (31.8)a 2 (9.1) 10 (45.5) 3 (13.6) 22
2 18 (32.1) 21 (37.5) 16 (28.6) 1 (1.8) 56
3 14 (56.0) 5 (20.0) 3 (12.0) 3 (12.0) 25
aNumber of patients (%). PD, progression of disease; NC, no change; PR,
partial response; CR, complete response.
Table 3 C-erb B-2 oncogene amplification and oncoprotein expression in
breast cancer
Oncogene Amplification [n(%)]a
Oncoprotein expression 0 2 > 2
0 81 (72) 5 (4) 0 (0)
1 + 7 (6) 3 (3) 2 (2)
2+ 4(4) 2 (2) 9(8)
aA total of 113 samples were assessed for c-erb B-2 DNA amplification and
oncoprotein expression.
Cells and tissues
Thebreast cancercell line SKBR3 (HTB 30) was obtained fromthe
American Type Culture Collection. Cells were cultured under
recommended conditions and served as positive control harbouring
an eightfold amplification of c-erbB-2. Pellets of cells were made
and 1% agarose was added to solidify the pellets, which were then
fixed in 10% buffered formalin for 1 day and embedded in paraffin
using standard protocols. Sections of paraffin-embedded patient
material were stained with haematoxylin and eosin, and 5-,um
sections for immunohistochemical studies were prepared from the
same paraffin blocks and mounted on gelatin-treated glass slides.
Histological grading
The tumours, both ductal and lobular carcinomas, were graded
according to the classification ofRichardson and Bloom modified
by Elston (1987). In the grading, three morphological features (the
tubule formation, the nuclear pleomorphism and the mitotic
frequency) were scored from 1 to 3.
Immunohistochemistry
c-erbB-2
A monoclonal antibody (NCL-CB 1; Novocastra Laboratories,
Newcastle upon Tyne, UK) reactive with the cytoplasmic part
of c-erbB-2 protein was used at 1:10 dilution with the
avidin-biotin-peroxidase immunohistochemical method (Vector
Laboratories, Burlingane, CA, USA). The specimens were counter-
stained with Mayer's haematoxylin for 1 min, rinsed in tap water
and mounted with Aquamount (BDH, Poole, UK). The stained
slides were evaluated by two investigators without knowledge of
patient information and the results were scored 0, 1 + (< 50% of
cells positive), 2 + (. 50% of cells positive). A known positive
control and a negative control were included in each batch.
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Table 4 The relationship between chemotherapy response and molecular
markers: c-erb B-2 oncoprotein expression, p53 and cathepsin-D
Degree of positivity Response to treatment
PD NC PR CR Total
c-erbB-2
0 32 (40.0)a 21 (26.3) 20 (25.0) 7 (8.8) 80
1+ 5 (55.6) 2 (22.2) 2 (22.2) 0 (0) 9
2+ 2 (14.3) 5 (35.7) 7 (50.0) 0 (0) 14
p53
0 31 (36.1)a 23 (26.7) 25 (29.1) 7 (8.1) 86
1+ 8 (47.1) 5 (29.4) 4 (23.5) 0 (0) 17
Cathepsin-D
0 8 (47.1)a 7 (41.2) 2 (11.8) 0 (0) 17
1+ 15 (41.7) 8 (22.2) 7 (19.4) 6 (16.7) 36
2+ 9 (29.0) 9 (29.0) 12 (38.7) 1 (3.2) 31
3+ 7 (41.2) 3 (17.7) 7 (41.2) 0 (0) 17
aNumber of patients (%).
p53
A monoclonal antibody (D07; Novocastra) reactive with both
wild-type and mutated p53 protein was used at 1:25 dilution to
stain the specimens. After storage, the slides were incubated
overnight at room temperature. They were not microwaved. A
nucleus with any positivity, when viewed under the microscope,
was interpreted as positive forp53 overexpression (score 0, < 10%
of cells positive; 1 +, > 10% of cells positive). A known positive
control and a negative control were included in each batch.
Cathepsin-D
A monoclonal antibody (clone I C II, TritonDiagnostics, Alameda,
CA, USA) that identifies both the 34-kDa and the 48-kDa forms of
cathepsin-D was used in the study. The slides were incubated at
1:20 dilution overnight at room temperature. The reaction posi-
tivity in tumour cells was graded on a scale ranging from 0 to 3 +
(1 +, < 10% of cells positive; 2 +, > 10% of cells positive; 3 +,
> 50% of cells positive). Again, a known positive control and a
negative control were included in each batch.
Polymerase chain reaction (PCR)
c-erbB-2-amplification analysis
The method described by Neubauer et al (1992) was used with
some modifications. One 5-gm paraffin section, without any
attempts to excise stromal tissue, was deparaffinized with xylene
and washed twice with absolute ethanol, pelleted and dryed under
vacuum. A volume of 100 ,ul containing 1 x PCR buffer (10 mm
Tris-HCl pH 8.3, 1.5 mm magnesium chloride, 50 mm potassium
chloride) was added and the mixture was heated to 95°C for 10
min. Between 1 10 ,ul of template DNA was then used for poly-
merase chain reaction, which consisted of 1 x PCR buffer, 200 jim
ofdNTPs (Promega Biotech), 0.5 gM ofprimers (or 0.1Igm for 85-
bp IFN) and 0.5 units ofAmplitaq DNA polymerase (Perkin-Elmer
Cetus) in a volume of 100,l. The reaction mixture was overlaid
with liquid paraffin (cycle 1: 94'C for 5 min, 50°C for 1 min, 72°C
for 1 min; cycles 2-34: 94°C for 1 min, 50°C for 1 min, 72°C for
1 min; cycle 35: 94°C for 1 min, 60°C for 10 min). Normal human
spleen cells andhuman breast cancercell line SKBR3 (ATCC) cells
served as negative and positive controls respectively. Finally, 10jtl
Table 5 Treatment group, c-erb B-2 oncoprotein, p53, cathepsin-D and
histological grade as predictors of time to progression after chemotherapy
(FEC)
Factor Hazard ratio (1 vs 0) P
Treatment group 2.00 < 0.001
C-erb B-2 1.09 0.53
p53 0.89 0.68
Cathepsin-D 1.00 0.60
Histological grade 1.80 <0.0005
aFactors: group (1, 2); c-erb B-2 (0-2); p53 (0, 1); cathepsin-D (0-3); grade
(1-3).
of the reaction products were run in 12% polyacrylamide non-
denaturing gel. After staining with ethidium bromide, the UV-illu-
minated gel was photographed, and the negatives (polaroid 665)
were analysed by densitometry (Hoefer GS 300). The results were
interpreted as described by Neubauer et al (1992) with some excep-
tions: samples exceeding ratio 3 in test IFN150/IFN182 were
included, if the three test reactions produced similar results when
c-erbB-2 was tested against larger (119 bp) and smaller (65 bp)
reference amplified products ofthe reference interferon gene.
Statistical analysis
The effect of the observed factors on time to progression (TTP)
and overall survival (OS) was calculated using the Cox propor-
tional hazard model. Factors included in the Cox analyses were
treatment group (monthly = 1, weekly = 2), c-erbB-2 degree of
positivity (0, 1 +, 2 +), histological grade (1, 2, 3), p53 degree
of positivity (0, 1 +), cathepsin-D degree of positivity (0, 1 +,
2 +, 3 +). Correlation between treatment response (progressive
disease = 0, no change = 1, partial response = 2, complete
response = 3) histological grade, c-erbB-2 and cathepsin-D
was tested with Spearman's rank correlation coefficient, and the
correlation between p53 and response was tested using the
Mann-Whitney U-test. Calculations were performed using the
Macintosh Statistica-program. The weighed kappa value for the
agreement between c-erb-B2 gene amplification and oncoprotein
expression was also calculated (Altman, 1991).
RESULTS
Of all the parameters assessed in this study histological grade
appeared to be the most valuable predictor of chemotherapy
outcome. As shown in table 2, the best response rate was observed
in patients with grade 1 tumours and the worst in the grade 3 group
(P < 0.001). In contrast, the histological subtype did not correlate
with treatment response. According to a multivariate analysis,
menopausal status did not correlate with other factors including
treatment response, TTP and histological grade.
C-erbB-2 amplification and expression were evaluated from
113 patient samples by semiquantitative PCR and immunohisto-
chemistry respectively. As shown in Table 3, both parameters were
closely related (P < 0.001), and therefore, for further statistical
analyses, the results from the oncoprotein expression analysis
were used. In addition to c-erbB-2 expression, p53 positivity and
cathepsin-D positivity were determined from tissue samples of
patients who were evaluable for chemotherapy outcome (Table 4).
None ofthese factors predicted treatment outcome.
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The laboratory data were also correlated with chemotherapy
outcome by univariate analysis (Table 5). As expected from an
earlier analysis of the clinical data (Blomqvist et al, 1993), time
to progression was prolonged statistically significantly when
chemotherapy was given every 4 weeks instead of once a week.
Again, c-erbB-2, p53 and cathepsin-D had no predictive value. In
contrast, histological grade turned out to be an important predictor
of treatment outcome (Table 5). Time to progression was delayed
among the patients with histologically proven grade 1 primary
tumours. This result was highly significant when data from all
patients was included in the univariate analyses (Table 5). The
results could be reproduced when data from the weekly and
monthly treatment groups were analysed separately (data not
shown). With respect to overall survival, none of the other factors
evaluated in this study had any predictive value (data not shown).
DISCUSSION
The tissue samples analysed in this study were obtained from a
selected group ofpatients. Eligible patients had developed metastatic
disease after removal ofthe primary tumour. The proportion ofcases
representing the most common histological ductal subtype was 74%.
This is close to the value (approximately 70%) that was observed in
a number of series based on Armed Forces Institute of Pathology
(McDivitt et al, 1968) and WHO (Scarff and Torlini, 1968) reviews.
However, the division of breast cancer samples into ductal and
lobular subtypes had no prognostic value in this study. This result is
in agreement with those presented by other investigators.
The histological specimens were also graded according to the
most widely used system. In the material that we used, 21.4%,
54.4% and 24.3% represented histological grades 1, 2 and 3 respec-
tively. The comparison of these results with those from other insti-
tutions is difficult to determine. It is well known that there is a wide
variation ofresults from different institutions (Stenkvist et al, 1983;
Gilchrist et al, 1985). In his review, Clayton (1991) found the
proportion of well-differentiated tumours to be between 3% and
33% and the proportion of poorly differentiated tumours to be
between 25% and 67%.
In the present study, the most powerful prognostic factor was
histological grade (Tables 3 and 6). Regardless of the treatment
schedule, the highest number of chemotherapy responders were
observed among patients with grade 1 primary tumours. This
outcome was not surprising. In a series of studies starting in 1973,
the Nottingham group (Blamey and Galea, 1994) discovered that
patients with poorly differentiated tumours, in addition to nodal
involvement, had very poor prognosis. Our results also suggest that
this factor cannot be changed by the administration of
chemotherapy. This is supported by a recent study, in which Aas et
al (1996) demonstrated that high histological grade was associated
with poor primary response to chemotherapy.
The Nottingham group (Blamey and Galea, 1994) has investi-
gated many prognostic factors including DNA ploidy, proliferative
index flow cytometry, hormone receptors, oncogenes, lectin
binding and vascular invasion. Yet, they have found that histolog-
ical grade consistently emerges as the most powerful variable. In
our institution, which is solely a cancer hospital, all the breast
cancer samples were evaluated by a single pathologist who
reviews, almost exclusively, tumour samples. This variable may
explain the strong prognostic value ofhistological grade.
In the present study, c-erbB-2 amplification was observed in
22.8% and c-erbB-2 overexpression in 31.4% of our patients.
Correlation between these two parameters was highly significant
(P < 0.001). These data agree reasonably well with results
presented by Klijn et al (1992). Based on a review of 11 408 breast
tumours, they observed that the incidence of amplification and
overexpression was 20.6% and 19.2% respectively.
There is an increasing amount of data on the predictive value of
c-erbB-2 for response to both endocrine therapy and chemo-
therapy (Klijn et al, 1992). Overexpression or amplification of the
oncogene in the tumour is considered to indicate poor response to
hormonal treatment. With regard to chemotherapy, there is no
consensus about response in patients with c-erbB-2 positive
tumours.
In our material, after staining with one antibody, the incidence
of p53 expression indicating the mutation of the gene was 16.5%
(Davidoff et al, 1991). This is lower than the incidence reported in
several other studies. By using various antibodies, p53 expression
has been shown to be present in 26-54% of primary breast carci-
nomas (Cattoretti et al, 1988; Bartek et al, 1990; Davidoff et al,
1991; Horak et al, 1991; Ostrowski et al, 1991; Walker et al, 1991;
Barbareschi et al, 1992; Isola et al, 1992; Poller et al, 1992). In
fact, the results seem, to a large extent, to depend on antibody
selection. Recently, Jacquernier et al (1994) in a series of 106
breast cancers detected p53 expression with at least one antibody
in 40 tumours (38%), whereas only 15 tumours (14%) were
positive with a cocktail of four antibodies. In our study, low p53
expression may have resulted from prolonged storage of slides
before immunostaining. At the time the slides were processed,
microwaving was not used. The wide variation in results as a result
of methodological differences may explain the lack of association
between p53 gene alterations and response to systemic treatment
(Klijn et al, 1993). Previously, Koechli et al (1994), using an in
vitro assay for chemosensitivity to CMF (cyclophosphamide,
methotroxate, fluorouracil), reported a significant correlation
between mutant p53 protein concentration and enhanced chemore-
sistance. Unlike the in vitro study, a single in vivo study supports
increased chemosensitivity in node-positive breast cancers (Allred
et al, 1993). More recently, investigators have failed to detect
statistically significant evidence that p53 status, as assessed by
immunohistochemistry, could predict clinical response to breast
cancer treatment (Elledge et al, 1995; Makris et al, 1995; Mathieu
et al, 1995). Our findings are in agreement with those reports.
Cathepsin-D positivity has been associated with poor prognosis
in general (Elledge et al, 1992) and in stage 1 and 2 breast cancer
in particular (Winstanley et al, 1993). As a predictor of treatment
outcome in systemic disease, cathepsin-D appears to have little
value. In two studies (Damstrup et al, 1992; Winstanley et al,
1993), in which over 300 patients followed hormonal therapy for
recurrent breast cancer, there was no correlation between
cathepsin-D levels in the primary tumour and the type ofresponse,
duration of response or length of post-relapse survival. Results in
the present study indicate that cathepsin-D expression in tumour
cells had no value in predicting response to chemotherapy, time to
progression or overall survival. This is in agreement with several
other studies (Tetu et al, 1993; Joensuu et al, 1995; O'Donahue et
al, 1995) demonstrating that in breast cancer cathepsin-D expres-
sion of tumour cells has no prognostic value. In contrast, analysis
of the same specimens showed that staining of stromal cells was
associated with poor survival.
Ourresults demonstrate that the assessment ofhistological grade
in the primary tumour by an experienced pathologist is the most
powerful predictor in the treatment of recurrent breast cancer with
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combination chemotherapy. In contrast, c-erbB-2 oncogene expres-
sion, p53 positivity and cathepsin-D positivity had no predictive
value in the same setting. This may reflect differences in methods
that have been used in various laboratories. Additionally, the
patient populations included in the studies may not be comparable.
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